Related Experiment Video
Updated: Apr 13, 2026
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Remimazolam versus midazolam for sedation in diagnostic upper gastrointestinal endoscopy: study protocol for a
Dong-Won Ahn1, Jun Kyu Lee2, Kwang Hyuck Lee3
1Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
Background:
Remimazolam is a new alternative drug combining the efficacy and safety advantages of midazolam and propofol. However, studies comparing remimazolam with midazolam in diagnostic upper gastrointestinal endoscopy are insufficient. The purpose of this study was to prove the efficacy and safety of remimazolam in diagnostic upper gastrointestinal endoscopy compared with midazolam.
Methods:
This study is a randomized, controlled, multicenter trial. Participants who are to receive diagnostic upper gastrointestinal endoscopy are enrolled and randomly assigned to the remimazolam or midazolam group (control group) at a 1:1 ratio. Remimazolam is given (with an initial 5 mg plus an additional 2.5 mg, maximum 5 times) in the remimazolam group for endoscopic sedation and midazolam is given (with an initial 2 mg plus an additional 1~2 mg, maximum 5 times) in the control group. Flumazenil can be given at the discretion of the investigator. Vital signs, level of consciousness, and adverse events are assessed from the administration of sedatives to the full recovery of consciousness. The primary endpoint is total procedure time, which is defined as the time from the first administration of sedatives to discharge. The secondary endpoints include the success rate of sedation, recovery time, induction time, total endoscopy time, discharge time, sedation time, incidence of hypotension, respiratory depression, tachycardia, bradycardia, participant satisfaction, and paradoxical response incidence.
Discussion:
The results of this trial are expected to prove the superior efficacy of remimazolam with favorable safety. Based on the results, a sedation method using remimazolam would be applied preferentially for diagnostic upper gastrointestinal endoscopy in clinical practice.
Trial Registration:
Clinicaltrials.gov NCT05836545. Registered on April 19, 2023.
More Related Videos
07:45Minimally Invasive Murine Laryngoscopy for Close-Up Imaging of Laryngeal Motion During Breathing and Swallowing
Published on: December 1, 2023
14:52Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
Published on: January 13, 2018
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:24Parenteral Anesthetics: Overview
01:24Upper GI Series: Barium Swallow
Purpose and Procedure
Patients undergoing this procedure ingest a liquid containing barium sulfate with a chalky...
01:22Stages of General Anesthesia
01:23Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...